

<b><u>PI3K/AKT/mTOR Pathway Inhibition</u></b>		<b><u>Phase</u></b>	<b><u>Status</u></b>
NCT01226316	Safety, Tolerability and Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules	I	Recruiting
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	I	Recruiting
NCT02646319	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	II	Recruiting

### **MAPK Pathway Inhibition**

NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade EOC or Peritoneal Cavity Cancer	II/III	Recruiting
-------------	---	--------	------------

### **Anti-Angiogenic Therapies**

NCT02558348	Phase I/IIa Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	I/II	Recruiting
NCT01669798	BIBF 1120 in Bevacizumab Resistant, Persistent or Recurrent Epithelial EOC	II	Recruiting

### **PARP Inhibition**

NCT02354586	A Study of Niraparib in Patients With EOC Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)	II	Recruiting
NCT02575651	A Phase I Study of Fluzoparib in Patients with Advanced Solid Malignancies	I	Recruiting
NCT02655016	A Study of Niraparib Maintenance Treatment in Patients with Advanced EOC Following Response on Front-Line Platinum-Based Chemotherapy	III	Recruiting

### **Combination PARPi/Anti-Angiogenesis**

NCT02446600	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	III	Recruiting
NCT03117933	Olaparib +/- Cediranib or Chemotherapy in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer (OCTOVA)	II	Recruiting

### **Immunotherapy + Chemotherapy**

NCT02520154	Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer	II	Recruiting
NCT02726997	Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)	I/II	Recruiting
NCT02718417	A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100	III	Recruiting
NCT02580058	A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (msb0010718c) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer	III	Active, Not Recruiting

NCT02923 739	A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT	II	Recruiting
NCT02839 707	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	III	Recruiting
NCT03245 892	Single center, non-randomized, open label, pilot study to evaluate the safety and tolerability of neoadjuvant and post-surgical dose dense paclitaxel and carboplatin chemotherapy in combination with nivolumab for the treatment of advanced high grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin.	I	Recruiting
NCT03038 100	A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	III	Recruiting

#### **Cell Cycle Checkpoint Inhibition**

NCT02659 241	A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer	I	Recruiting
-----------------	---	---	------------

#### **Immunotherapy Combination**

NCT03026 062	Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	II	Recruiting
NCT02498 600	Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	II	Active, Not Recruiting

#### **Folate Receptor Antagonist Therapy**

NCT02631 876	FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer	III	Recruiting
NCT02606 305	Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer	I	Recruiting

**Supplementary Table 4. Ongoing ovarian cancer clinical trials.**